Many studies have shown that the efficacy and risk of side effects of drug treatment is
influenced by genetic variants. Evidence based guidelines are essential for implementing …

Simple Summary Acquired resistance to chemotherapy by cancer cells is the predominant
factor in chemotherapy failure, which ultimately leads to disease progression and death …

Pharmacogenetics (PGx) studies the influence of genetic variation on drug response.
Clinically actionable associations inform guidelines created by the Clinical …

Background: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the
systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side …

Precision medicine is increasingly recognized as a promising approach to improve disease
treatment, taking into consideration the individual clinical and biological characteristics …

Abstract The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx
implementation by developing evidence-based pharmacogenetics guidelines to optimize …

Preemptive targeted pharmacogenetic testing of candidate variations in DPYD is currently
being used to limit toxicity associated with fluoropyrimidines. The use of innovative next …

Fluoropyrimidines are widely used in the treatment of several types of solid tumors. Although
most often well tolerated, severe toxicity is encountered in~ 20–30% of the patients …

Simple Summary 5-Fluorouracil (5-FU) is a chemotherapy drug that is commonly used to
treat multiple cancers. Many people who are treated with 5-FU experience severe toxicity to …

Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the
treatment of cancer, especially gastrointestinal tumors and breast cancer, but their …